Icade opens the week with a full agenda, shares framed by French property sector

Icade starts the week with a packed calendar in French real estate. The focus for investors is the next earnings update and how the stock compares to peers like Gecina and Covivio in a cautious office market.

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-29, 13:06.

Icade (FR0000035081) starts the new week with a full agenda in the French listed property space. The Paris-based landlord sits alongside peers such as Gecina and Covivio on Euronext Paris as investors look ahead to the next earnings update.

What the company reports

Icade positions itself as a major French real estate group with activities in commercial property investment and property development, with a portfolio focused on offices and healthcare assets. The group’s investor relations page highlights recurring income from rental properties and development projects, underlining a diversified earnings base across segments.

In the most recent full-year publication for 2025, Icade reported net current cash flow and portfolio valuations that reflected the adjustment in European office markets to higher interest rates, a theme also evident at peers Gecina and Covivio. The company’s reporting structure separates property investment from development, which helps investors track earnings visibility and project-driven volatility over the calendar year.

Focus on upcoming earnings

The earnings calendar on Icade’s investor relations website outlines a regular pattern of half-year and full-year results, with management presentations typically held in Paris and by webcast for international investors. While the exact next date is not prominently flagged today, the group traditionally reports first-half figures in late July or early August, a timetable broadly in line with other Euronext Paris property names.

For retail investors, this rhythm matters because rental income and valuation adjustments in the first half often set the tone for guidance and dividend expectations for the rest of the year. In the French office market, analysts covering landlords such as Gecina and Covivio have recently emphasized occupancy rates, lease spreads and debt costs as key metrics, which also apply to Icade’s results.

The business behind Icade’s earnings

Icade generates most of its cash flow from rental income on office and healthcare properties, complemented by margins on development projects such as residential and mixed-use schemes. The group’s portfolio is mainly located in the Paris region and other major French urban areas, with a focus on long-term leases to corporate tenants and healthcare operators.

In recent reporting, Icade has emphasized its exposure to the healthcare real estate segment, which tends to provide more stable occupancy and cash flow compared with traditional office assets. This is consistent with a broader strategic shift among European property companies towards segments with more resilient demand, such as healthcare and logistics, as highlighted in sector commentary from analysts covering Gecina, Covivio and other REIT-style structures.

Where the Icade shares trade

Icade shares (FR0000035081) are listed on Euronext Paris, with trading in euros. A current, precise price quote and market capitalization for the stock are not reliably available in live data checks today, so investors should refer directly to Euronext Paris or major financial portals for the latest intraday price.

Key data on the Icade shares

• Company: Icade S.A.
• ISIN: FR0000035081
• WKN: 403291
• Ticker: ICAD
• Trading venue: Euronext Paris
• Sector / industry: Real Estate Investment & Development
• Index membership: Listed on Euronext indices for French real estate; investors often compare Icade with Gecina and Covivio in the sector context.
• Next earnings date: Not officially scheduled

Disclaimer: This article provides factual information on the Icade shares and the company’s business. It is not investment advice and does not contain any recommendation to buy or sell the stock.